Literature DB >> 8085966

Endothelin receptor-binding subtypes in the human retina and choroid.

M W MacCumber1, S A D'Anna.   

Abstract

PURPOSE: Endothelins (ETs) are a family of vasoconstrictive peptides produced in part by vascular endothelial cells. They are synthesized in the eye, particularly in the uveal tract, and can markedly constrict the iris and preretinal vessels in the rabbit eye. Two ET receptor subtype families have been characterized and cloned, termed ETA and ETB. To better understand the distribution of ocular ET receptors, we localized ET receptor-binding sites in human and rabbit eyes.
METHOD: Autoradiography with iodine 125-labeled ET-1 and varying concentrations of unlabeled ET-3 was used to localize ET receptor-binding subtypes in the posterior pole of human and rabbit eyes.
RESULTS: The ETA-like receptor-binding sites are localized to the retinal and choroidal blood vessels, whereas the ETB-like receptor-binding sites are localized to the neural and glial substance of the retina.
CONCLUSIONS: Endothelin receptor-binding subtypes are differentially located in the posterior pole of human and rabbit eyes. Endothelin peptides released within the retina and choroid may participate in the ocular manifestations of a variety of systemic disorders, including systemic hypertension.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8085966     DOI: 10.1001/archopht.1994.01090210119024

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  16 in total

1.  Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients.

Authors:  A Gass; J Flammer; L Linder; S C Romerio; P Gasser; W E Haefeli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

2.  Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma.

Authors:  M Emre; S Orgül; T Haufschild; S G Shaw; J Flammer
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

Review 3.  Endothelin antagonism as an active principle for glaucoma therapy.

Authors:  Rita Rosenthal; Michael Fromm
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Plasma endothelin-1 concentrations in patients with retinal vein occlusions.

Authors:  A Iannaccone; C Letizia; S Pazzaglia; E M Vingolo; G Clemente; M R Pannarale
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

5.  Black currant anthocyanins normalized abnormal levels of serum concentrations of endothelin-1 in patients with glaucoma.

Authors:  Kaori Yoshida; Ikuyo Ohguro; Hiroshi Ohguro
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-21       Impact factor: 2.671

6.  Preoperative duration of retinal detachment and subretinal immunoreactive endothelin-1: repercussion on logarithmic visual acuity.

Authors:  Manuela Roldán-Pallarès; Abdalla-Sadiq Musa; Carmen Bravo-Llatas; Raquel Fernández-Durango
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-25       Impact factor: 3.117

Review 7.  Eyeing endothelins: a cellular perspective.

Authors:  Ganesh Prasanna; Santosh Narayan; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

8.  Functional and molecular characterization of the endothelin system in retinal arterioles.

Authors:  Travis W Hein; Yi Ren; Zhaoxu Yuan; Wenjuan Xu; Sonal Somvanshi; Taiji Nagaoka; Akitoshi Yoshida; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

9.  Endothelin B receptors contribute to retinal ganglion cell loss in a rat model of glaucoma.

Authors:  Alena Z Minton; Nitasha R Phatak; Dorota L Stankowska; Shaoqing He; Hai-Ying Ma; Brett H Mueller; Ming Jiang; Robert Luedtke; Shaohua Yang; Colby Brownlee; Raghu R Krishnamoorthy
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

10.  Molecular mechanisms of retinal ganglion cell degeneration in glaucoma and future prospects for cell body and axonal protection.

Authors:  Yasunari Munemasa; Yasushi Kitaoka
Journal:  Front Cell Neurosci       Date:  2013-01-09       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.